Standard Motor Products Inc. (NYSE:SMP) shares decreased -1.16% in last trading session and ended the day at $35.80. SMP Gross Margin is 29.00% and its has a return on assets of 7.50%. Standard Motor Products Inc. (NYSE:SMP) quarterly performance is 1.32%.
Standard Motor Products (NYSE: SMP) declared a quarterly dividend of $0.17 per share, or $0.68 annualized. This is a 13.3% increase from the prior dividend of $0.15. The dividend will be payable on March 1, 2016, to stockholders of record on February 16, 2016, with an ex-dividend date of February 11, 2016.
Ford Motor Company (NYSE:F) ended the last trading day at $12.20. Company weekly volatility is calculated as 4.11% and price to cash ratio as 3.30. Ford Motor Company (NYSE:F) showed a weekly performance of -6.94%.
Ford Motor Company (NYSE:F) CEO Mark Fields said delivering strong results is the best way for the automaker to counter the skeptics on Wall Street. The drop was Ford’s biggest one-day percentage loss in 15 months. It followed Ford’s announcement Tuesday of a record pretax profit in 2015 and projection that it would match or beat that performance in 2016.
On 13 January, Pointer Telocation Ltd. (NASDAQ:PNTR) shares decreased -0.83% and was closed at $5.50. PNTR EPS growth in last 5 year was 42.90%. Pointer Telocation Ltd. (NASDAQ:PNTR) year to date (YTD) performance is -11.65%.
Zacks Investment Research upgraded shares of Pointer Telocation Ltd (NASDAQ:PNTR) from a hold rating to a buy rating in a research note published on Wednesday morning, Marketbeat.com reports. The brokerage currently has $6.25 target price on the stock.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares decreased -6.36% in last trading session and ended the day at $4.86. SPPI Gross Margin is 82.00% and its has a return on assets of -10.70%. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) quarterly performance is -18.73%.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Servier Canada Inc., announce the signing of a strategic partnership. As part of this partnership, Spectrum will grant the exclusive rights to develop and commercialize in Canada a franchise of four Spectrum hemato-oncology drugs: ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, Folotyn®(pralatrexate injection), Beleodaq® (belinostat) for Injection and Marqibo® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) caters to the Healthcare space. Its weekly performance is -10.62%. On the last day of trading company shares ended up at $1.01. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) distance from 50-day simple moving average (SMA50) is -9.64%.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) provided a clinical development update for bavituximab, the company’s investigational phosphatidylserine (PS)-targeting immunotherapy. In the first quarter of 2016, Peregrine plans to initiate two new Phase II clinical trials in breast and lung cancer in combination with current standard of care treatments including both chemotherapy and immuno-oncology agents.